ACADIA Pharmaceuticals Inc. vs OneSpan Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.84 (market cap $5.07B), while OneSpan Inc trades at $16.25 (market cap $600.69M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 8.4× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | OSPN | |
|---|---|---|
Market Cap | $5.07B | $600.69M |
Sector | Health | Technology |
52-Week High | $29.41 | $16.78 |
52-Week Low | $20.06 | $10.15 |
Enterprise Value | $4.19B | $569.77M |
Dividend Yield | — | 3.19% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →